Research

Ticker Move of the Day: T -5.27% as SpaceX pushes to launch 4th wireless carrier

Support · 1 min read · Oct 23, 2026, 7:30 AM PT

AT&T shares slid 5.27% in regular trading on October 23 as Bloomberg reported that SpaceX is in talks for access to approximately 80,000 U.S. cell tower sites to build a fourth nationwide wireless carrier. The talks with major tower companies including Crown Castle represent SpaceX's latest move to complement its earlier October acquisition of 800 MHz spectrum from Grain Management. This fresh competitive threat compounds pressure on AT&T and peers T-Mobile and Verizon, all down sharply in both early and regular trading. While no tower leases are yet signed and the spectrum deal closes only in the first half of 2027, the convergence of SpaceX's satellite infrastructure, spectral assets, and tower access negotiations suggests a material competitive test ahead for legacy carriers. Investors are now focused on whether SpaceX can convert tower discussions into binding contracts and how quickly Starlink Mobile can operationalize as a terrestrial competitor.

Research

Ticker Move of the Day: BHVN +30% after FDA accepts Vyglxia NDA resubmission

Support · 1 min read · Oct 22, 2026, 7:30 AM PT

Biohaven Pharmaceuticals (BHVN) surged 30.3% in regular trading on October 22 after the FDA accepted its resubmission of the new drug application for Vyglxia (troriluzole), a treatment for spinocerebellar ataxia. The regulatory milestone signals the agency will complete its review under a standard timeline, potentially moving Vyglxia closer to commercial availability. Separately, Biohaven announced a $100 million non-dilutive licensing deal with Ono Pharmaceutical for its MoDE IgG degrader portfolio in Asian territories, retaining US and European rights for future monetization. The dual catalysts—regulatory progress on a mid-stage asset plus significant cash partnering revenue—address two key concerns for a clinical-stage biotech: development velocity and cash runway. Traders are now watching for the FDA's target action date and Phase 3 progress on BHV-1300 for Graves' disease.

Research

Ticker Move of the Day: SMCI +11.52% on blowout Q1 revenue guidance beat

Support · 1 min read · Oct 21, 2026, 7:31 AM PT

Super Micro Computer (SMCI) surged 11.52% in regular trading on October 21 following the company's late Tuesday announcement of preliminary first-quarter fiscal 2027 revenue of $18.5–$19.5 billion, crushing both prior guidance of $14.5–$15.5 billion and analyst consensus near $15 billion. The server maker also raised gross margin guidance to 12.0–12.5% from 10.4–10.8%, signaling improved profitability. The upside revision was driven by explosive demand for artificial intelligence server platforms, with implied year-over-year revenue growth of approximately 280%. Supermicro's guidance lift is expected to boost the entire AI infrastructure sector, including peers like Dell and HPE, and eases investor concerns about AI spending sustainability. The company will report official earnings on November 3, 2026 at 5 p.m. EST.

Research

Ticker Move of the Day: BRZE +51% after Salesforce agrees to acquire for $5.66B

Support · 1 min read · Oct 20, 2026, 7:30 AM PT

Braze (BRZE) surged 51% in regular trading on October 20 following Salesforce's announcement of a definitive agreement to acquire the customer engagement platform for approximately $5.66 billion in enterprise value. Salesforce will pay $47.50 per share in cash, representing a 58% premium to Braze's prior close of $30.04 on October 18. The acquisition strengthens Salesforce's Marketing Cloud and AI-powered customer engagement capabilities by integrating Braze's real-time messaging and personalization technology across mobile apps, web, email, SMS, and other channels. The transaction is expected to close in Salesforce's fiscal year 2028, subject to regulatory and shareholder approval, with Salesforce maintaining its fiscal 2027 guidance and funding the deal entirely from cash. Braze is now backed by customer giants including Canva, Instacart, Urban Outfitters, and Venmo, with recent reported revenue growth of 26.2% year-over-year to $227.2 million in the latest quarter.

Research

Ticker Move of the Day: FMC -34% after catastrophic Q3 guidance cut

Support · 1 min read · Oct 15, 2026, 7:30 AM PT

FMC Corporation stock plummeted 34% in regular trading on October 15 following a devastating pre-market guidance revision that shocked the market. The agricultural sciences company slashed its third-quarter revenue guidance to $65–$125 million from a prior $840–$900 million, and swung EBITDA guidance to a loss of $510–$565 million from a $120–$140 million profit. Management attributed the collapse to weaker-than-expected demand and bloated channel inventory, forcing aggressive commercial actions including targeted price cuts and a restructuring of U.S. pricing and sales operations. The combination of a 52-week low stock price, $625–$675 million in one-time impacts, and years of crop-protection pricing headwinds has triggered rapid analyst target cuts from major banks. Full third-quarter results and 2027 guidance will follow on October 29, leaving investors to assess whether management's structural turnaround can stabilize the deeply distressed balance sheet.

Research

Ticker Move of the Day: BSP +33% after Berkshire Hathaway $330M private placement

Support · 1 min read · Oct 14, 2026, 7:30 AM PT

Bending Spoons (BSP) surged 33% in regular trading on October 14 following Berkshire Hathaway's announcement of a $330 million private placement, increasing the investment giant's stake to 4%. The Italian software conglomerate is now backed by $930 million of Berkshire capital since its July 2026 IPO. Berkshire purchased 10 million shares at $33 per share, signaling continued confidence in BSP's AI-driven acquisition and operational-improvement strategy. The company has rapidly grown revenue through strategic acquisitions including Miro, Airtable, and others, posting 126% revenue growth in Q2 2026. Traders should monitor BSP's ability to sustain valuation multiples—currently trading at a trailing P/E of 180—as integration execution and organic growth metrics will determine whether Berkshire's large bet justifies its premium pricing.

Research

Ticker Move of the Day: NKE -5.2% after earnings miss and weak 2027 guidance

Support · 1 min read · Oct 02, 2026, 7:30 AM PT

Nike (NKE) fell 5.2% during Friday's regular session to $33.27, extending losses from Thursday's post-earnings sell-off, after the athletic apparel company reported fiscal first-quarter revenue of $11.21 billion that missed analyst expectations and guided for high-single-digit revenue declines in fiscal 2027. The company's adjusted earnings per share of $0.48 beat expectations, but the bleak outlook and plans to cut staff in 2027 overshadowed the earnings beat, as Greater China revenue collapsed 26% and Nike Sportswear declined in the low double digits. CEO Elliott Hill acknowledged the company needs significant time to reset its troubled sportswear, Jordan, and China businesses under the new "Pace" restructuring plan, which targets $2.5 billion in cost savings by 2031. Analysts have slashed price targets this week, with Telsey Advisory downgrading to Market Perform at $35 and UBS warning investors against "catching a falling knife" as the stock now trades near its lowest level since 2014. Nike's year-to-date decline of nearly 45% and exclusion from the S&P 100 underscore the severity of the turnaround challenge ahead.